Piodema gangrenoso

Maldonado, Silvina D.
Dermatol. argent ; 7(2): 93-112, abr.-jun. 2001. ilus
Artículo en Español | LILACS | ID: lil-310919

Documentos relacionados

  1. Investigation and management of the monoclonal gammopathy of undetermined significance: A British Society for Haematology Good Practice Paper.
  2. A review of clinical guidelines, laboratory recommendations and external quality assurance programs for monoclonal gammopathy testing.
  3. Monoclonal gammopathy of clinical importance.
  4. The promise and harms of screening for plasma cell dyscrasias.
  5. M-protein-related disorders: MGCS.
  6. [Monoclonal gammopathies: from MGUS to multiple myeloma].
  7. Monoclonal gammopathy of increasing significance: time to screen?
  8. The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception.
  9. Vitamin D and monoclonal gammopathy of undetermined significance (MGUS) among U.S. Black women.
  10. The force awakens, but questions remain: The future of MGUS.